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ABSTRACT 
 
The ketogenic diet (KD) is a restricted carbohydrate, high fat and sufficient protein metabolic 
therapy that elevates ketones as an alternative fuel source, and that reduces seizures in persons 
with epilepsy which is often comorbid with autism. Autism is characterized by communication 
deficits, decreased sociability and repetitive behaviours. A restrictive KD reverses symptoms in 
the BTBR mouse model of autism but its severity is a factor in its clinical applicability. In a 
study with the EL mouse model of epilepsy and autism, sex-dependent effects were found where 
only females displayed the behavioural effects of the KD. In the current study, a strict and a 
milder KD were tested on female EL mice to compare their effects on behavior, blood chemistry 
and body weight. This study investigated if increased ketones and lowered blood glucose were 
necessary for behavioural improvement. In order to do so, female EL mice were fed either a 
standard rodent chow control diet, the restrictive KD or the moderate KD from five weeks of 
age. At eight weeks of age, behavioral testing, using the 3-chamber test which measures 
sociability and self-directed repetitive behaviour (grooming), were conducted in order to 
determine whether autistic symptoms were still present. In addition, the social transmission of 
food preference test which measures sociability as well was carried out. Weight, blood glucose 
and ketone levels were also measured. The diets had very similar behavioural effects on the 
animals, increasing sociability and reducing repetitive behaviours. Interestingly, the moderate 
KD caused increased weight and did not lower blood glucose yet still improved autistic 
behaviours. This suggests that caloric restriction and lowered blood glucose may not be 
necessary for improved behaviours as had previously been thought. Also, a clinical strength KD 
may possibly be beneficial for autistic children and should be further studied. 
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INTRODUCTION 
Autism  
Diagnosis and Prevalence 
 
Autism Spectrum Disorder (ASD) is a neurodevelopmental syndrome that is 
characterized by deficits in social reciprocity and in communication, as well as by unusual, 
restrictive, repetitive behaviours (Lord et al., 2000).  Social impairments include reduced social-
emotional reciprocity, not seeking to share enjoyment, difficulty forming relationships with peers 
and using non-verbal communication poorly. Communication deficits include improper 
acquisition of speech with compensation through other methods of communication, using 
stereotyped speech or delayed echolalia and/or difficulties having conversations. Limited 
imitative and/or imaginative play also often occur and are associated with abnormal social and 
communication abilities. Restrictive and repetitive behaviours are characterized by unusual 
fixations and limited interests, repeated hand and finger movements, whole bodily mannerisms, 
compulsive ritualistic behaviours, repetitive use of objects and odd sensory seeking behaviours 
(Lord and Bishop, 2010). Autism usually manifests from infancy, at the latest in the first three 
years of life (Lord et al., 2000) and is termed a pervasive developmental disorder because many 
aspects of cognition and behaviour of an affected individual are affected and because symptoms 
present during development from infancy or even from birth (Walsh et al. 2008). Behavioural 
symptoms of autism may first appear around 1-2 years of age and the diagnosis is made around 
2-4 years of age (Courchesne et al., 2007). Currently, there are still no biological markers to help 
diagnose autism and it remains behaviourally defined (Anagnostou and Taylor, 2011). 
Within the revised fifth edition of the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-V) are several changes to the diagnostic criteria of ASD. The revisions include 
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only two symptom domains (repetitive, obsessive interests and social-communication), removed 
subtypes of ASD and describe differences on an individual basis specifically by levels of severity 
in the two domains relative to levels of development and age. Therefore, an individual diagnosed 
with ASD would be described on the basis of how severe their symptoms of social-
communication and repetitive, restricted behaviours and interests are. This diagnosis could also 
be linked with other disorders such as genetic and medical conditions (e.g. ASD and Rett 
Syndrome or ASD and Fragile X), language disorders or other psychiatric conditions (e.g. ASD 
with intellectual disability or ASD with Attention Deficit Hyperactivity Disorder (ADHD)).  
Developmental standards for describing symptoms are also important elements of the revised 
DSM. Some symptoms like unusual social gaze, facial expressions and gestures are seen in 
autistics across all age and skill levels. However, some symptoms are expressed differently 
across development. For instance, a talkative autistic 10 year old girl cannot be diagnosed using 
the same symptom criteria for a two year old without expressive spontaneous language or for an 
adult with a better stocked repertoire of functional language. Delineating symptoms by age and 
development is important for improving understanding of the specificity of deficits in autism. 
The DSM-V also proposes that autistic individuals would be expected to have a history of each 
of the sub-domains that define social-communication (significant deficits in non-verbal 
communication, reduced social reciprocity and peer relationships) and two out of three areas of 
repetitive behaviours and fixated interests (repeated motor or verbal behaviours that include 
sensory responses; rituals and routines; obsessive interests). Providing examples that are specific 
for different age and developmental levels should result in greater sensitivity to diagnoses (Lord 
and Bishop, 2010). 
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 The Centers for Disease Control (CDC) estimates that 1 in 68 children has been identified 
with ASD across the US. The most significant risk factor for being autistic is being male; boys 
are almost five times more likely to have autism than girls: 1 in 42 boys versus 1 in 189 girls. 
Additionally, white children are more likely to be diagnosed with ASD than are black or 
Hispanic children (CDC, 2014). Several recent studies, though not always consistent, have found 
that parents’ (both mothers and fathers) advanced age is also correlated with increased risk of 
ASD. ASDs also incur large financial costs to families and society with affected families 
estimated to pay more than $3-5 million dollars beyond the typical cost of raising a child. The 
cost of ASD in the United States is almost $90 million dollars per year.  In comparison to other 
children with specialized needs, autistic children are underserved, with inadequate healthcare, 
less family-oriented care and greater hardships with referrals. Families of autistic children are 
also under greater financial burden, significantly coordinate their own children’s healthcare 
(greater than 10 hours per week) and will more likely stop or cut back work than other families 
of children with special needs (Lord and Bishop, 2010).  
Abnormal Brain Structure and Etiology of Autism 
 
 Presently, one of the most consistent findings of neuropathology of ASD is that of 
accelerated brain volume growth during early postnatal life. Studies of head circumference, 
which proxies for brain size, have shown that head circumference is normal or smaller at birth 
but that growth rate increases at around 12 months. MRI studies have shown that autistic 
children from ages 18 months to 4 years show a 5%-10% increase in total brain volume 
compared to age-matched controls. However, it is unclear whether this enlargement continues on 
into adolescence and adulthood (Amaral et al., 2008). The enlargement appears to occur in both 
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grey and white matter and studies suggest that white matter contributes disproportionately to this 
increase in volume (Anagnostou and Taylor, 2011).  
 A crucial question to address is whether there are region-specific abnormalities in brain 
volume. The general consensus from the postmortem literature on the older child or adult 
afflicted with ASD contrasts with that of the postnatal brain overgrowth. Older autistic brains are 
characterized by neuron loss, degeneration, inflammation and decreased size of the cortical 
minicolumns (Amaral et al., 2008). Studies that used stereological methods to quantify neurons 
found that there were fewer neurons in the amygdala which is important for memory, learning 
and emotion. The amygdala in autistic boys undergoes abnormal enlargement that continues 
through late childhood. Studies have found a 13%-16% enlargement in the amygdala of autistic 
children ages 36-56 months (Sparks et al., 2002). Other studies have suggested that enlargement 
of the amygdala is connected with very severe anxiety (Juranek et al., 2006) and abnormal 
sociability and communication (Munson et al., 2006). In typically developing boys, from ages 8-
18 years, the amygdala has increased in size by approximately 40% whereas this growth pattern 
was not seen in autistic boys. Therefore, the amygdala appears to initially be larger in autistic 
children but is not subject to the same volume increase that occurs in typically developing boys 
(Schumann et al., 2004). When the cerebellum was examined in autistics across a wide age 
range, it was found that the total volume was enlarged compared to controls (Amaral et al., 
2008). The cerebellum, which is important for its involvement in various cognitive and motor 
functions, has been found to have fewer Purkinje cells which would result in the cerebellum 
functioning improperly (Bailey et al., 1998). This finding has yet to be confirmed with 
stereological studies but studies have observed astrogliosis in the cerebellum which may indicate 
that glial activation had taken place upon neuronal degeneration or death. Other studies have 
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found that the neurons within the deep cerebellar nuclei, which is the pathway that leaves the 
cerebellum, were unnaturally small and pale in autistic adolescents and adults. The cerebellar 
vermis, which possibly has functions in modulating emotion, sensory perceptiveness and arousal 
has been found to be smaller or similar in size in autistics than in typically developing children, 
adolescents and adults (Courchesne et al., 2007). The corpus callosum, which contains 
interhemispheric axons, has consistently been said to have decreased volume in ASD which may 
suggest decreased interhemispheric connectivity in this group (Anagnostou and Taylor, 2011). In 
the frontal cortex which executes higher order functions, increases in pro-apoptotic molecules 
and decreases in anti-apoptotic molecules were found in adult autistics. Studies have found signs 
of glial activation in the cerebrum. Both glial activation as well as pro- and anti-inflammatory 
molecules have also been found in the frontal cortex. In addition, smaller minicolumns have been 
found in the frontal and temporal cortices of older children, adolescents and adults with ASD. 
More studies, however, need to be carried out on the pathology of neurons and the numbers of 
minicolumns in ASD across all ages (Courchesne et al., 2007). Findings have also consistently 
shown reduced intercolumnar width of layer III in the dorsolateral prefrontal cortex or 
Brodmann’s Area 9. Studies have reported the enlargement of the caudate nucleus which may be 
associated with repetitive and ritualistic behaviours in autistic adolescents and young adults. 
Evidence, though somewhat inconsistent, has been found for abnormal volume and shape of the 
hippocampus with greater cell packing density and smaller neurons being reported (Amaral et 
al., 2008). Investigations of structure have also reported reduced cingulate size in relation to 
decreased metabolic activity in autistics. In addition to the abnormalities in volume of the frontal 
and temporal lobes described above, volumetric abnormalities have also been found in the 
parietal lobe, thalamus and brainstem (Anagnostou and Taylor, 2011). 
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 Technologies that have only become recently available allow for the quantification of the 
grey and white matter. Enlargements have been found in grey and white matter in the frontal, 
temporal and parietal lobes, with the greatest increases being reported to be in the dorsolateral 
prefrontal and medial frontal cortex. Evidence on grey matter volume indicate that though grey 
matter increases may be proportionately smaller than white matter increases in early life, the 
increases may continue on into later life. Studies spanning childhood to adulthood found a 6%-
12% increase in grey matter (Palmen et al., 2005). Some MRI studies have found cortical shape 
abnormalities within the sylvian fissure, the superior temporal sulcus, the intraparietal sulcus and 
the inferior frontal gyrus (Nordahl et al., 2007). Two studies investigating cortical thickness 
found that in 8-12 year olds, there is increased cortical thickness over the entire cerebrum 
primarily caused by increases in temporal and parietal cortices whereas in adults there was 
cortical thinning in the frontal, parietal and temporal areas (Hardan et al., 2006). An MRI study 
involving older and preadolescent autistic children divided white matter into inner and outer 
compartments and found that the outer portion of white matter, especially in the frontal lobes, 
was significantly disturbed. Consistent with other cortical data was the fact that the occipital 
lobes were least deviant (Herbert et al., 2004). These findings suggest that ASD’s 
neuropathology may include increases in short-distance connections, particularly in brain regions 
that are responsible for higher language, cognitive, social and emotional functions (Courchesne 
et al., 2007). 
 There are also several hypotheses regarding the causal factors of autism. Genetic studies 
in autism are highly focused on mutations of the methyl-CpG-binding protein mecp2. Simply 
put, MeCP2 is a transcriptional repressor protein that has been found to be involved in gene 
silencing, particularly in the brain. Rare mutations of this gene have been identified in autistic 
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individuals. Mecp2 is an X-linked gene which makes it susceptible to X-inactivation and its 
mutations may result in neurodevelopmental disorders like autism. X chromosome inactivation 
decreases the number of X chromosomes transcribed to one per diploid set of autosomes which 
equalizes the distribution between sexes. The high prevalence of autism among males suggested 
the involvement of X-chromosome linkage which was later evidenced to be true from genome-
wide screens (Currenti, 2009). Many other potential genes and their mutations have been 
identified to be associated with ASD including SHANK3, NLGN3/4, CNTNAP2 and PNET to 
name a few. Evidence for the genetic role in the etiology of autism has also been derived from 
studies of twins. The concordance rate for monozygotic (MZ) and dizygotic (DZ) twins differs 
greatly with an MZ:DZ ratio being approximately 10:1. In twin studies, it was found that 
estimates of heritability or genetic causes in ASD ranged from 36% to 93% (Ronald and 
Hoekstra, 2011). These conclusions are consistent with a genetic etiology for ASD (Buxbaum, 
2009).  
The immune system may also play a role in ASD. Children, in utero, are provided with 
maternal antibodies, essential for providing the developing fetus with humoral immune system 
proteins. Some studies show that in mothers of children with ASD, however, maternal 
immunoglobulin reacts against fetal brain proteins. This hypothesis suggests that transfer of 
maternal antibodies via placenta negatively affects fetal brain development. Other studies on 
mice have shown that maternal infections during pregnancy enact changes in pro-inflammatory 
cytokines in the fetal mouse brain, significantly affecting brain development of the fetus. 
Moreover, families affected with ASD exhibit with autoimmune disorders. Neurotoxic exposure 
to heavy metals, such as mercury, has also been linked to ASD. The Food and Drug Association 
estimates that 16% of women have sufficiently high mercury levels to induce neurological 
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damage in their children and a reduced ability to excrete mercury is associated with ASD. 
Another hypothesis, the Redox/Methylation hypothesis, expounds that genetic and 
environmental factors combine to give a measure of the risk associated with developing autism. 
The hypothesis postulates that in most cases of autism, environmental exposures (heavy metals, 
xenobiotics) are clearly seen to be a factor but genetic factors still dictate the population at risk 
via polymorphisms (Currenti, 2009). Perhaps with further study, clear risk factors and biological 
markers can be delineated for autism and timely intervention provided for children at risk. 
Comorbidities 
 
Apart from its core symptoms, ASD is often accompanied by various psychological and 
physiological disorders. Epilepsy has been found to be frequently comorbid with ASD with the 
frequency range being 5% to 38.3% (Tuchman and Rapin, 2002). Epilepsy is defined as two 
unprovoked seizures of any type. Therefore, any seizures with a specified cause such as trauma, 
infection, metabolic illness or febrile seizures are not classified as epilepsy. The prevalence of 
epilepsy among all children is only 2% to 3% compared to the much higher rate among autistic 
children. Such a high proportion eliminates coincidence and suggests that epilepsy and autism 
may share underlying neurobiology (Tuchman and Rapin, 2002). The peak risk periods for 
seizures occur in early childhood before five years of age and in adolescence after ten years of 
age (Tuchman and Rapin, 2002; Bauman, 2010). Seizures become more apparent after 12 years 
of age with 66.7% of all seizures that accompany ASD occurring then and 30% occurring by age 
20 (Bauman, 2010). Certain gene mutations, such as those governing ligand- and ion-gated 
channels, have been found in both ASD and epilepsy (Betancur and Coleman, 2013). 
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 Autistic children also commonly suffer several other disorders. Children with ASD 
frequently suffer from sleep disorders with prevalence rates ranging from 40% to 80%, compared 
to typically developing children with rates of only 30%. Sleep disorders are also reportedly more 
severe in ASD with the most common being sleep onset, sleep maintenance and sleep duration. 
Metabolic disorders have also been associated with ASD including phenylketonuria, creatine 
deficiency syndromes, Wilson’s disease, Lesch-Nyhan syndrome and urea cycle disorders. There 
is also a growing body of evidence that suggests that mitochondrial dysfunction may play a role 
in at least a subgroup of autistic individuals. The prevalence is currently unknown but 
mitochondria supply a very substantial amount of energy to the cell and, therefore, will mostly 
affect tissues with high energy demands such as the brain (Bauman, 2010). The prevalence of 
mental retardation in idiopathic autism has been estimated to be ~60% but with the spectrum 
taken into consideration, the prevalence drops to 30%. Mood and anxiety disorders are also very 
common in ASD (Amaral et al., 2008). 
Treatment 
 
 Several treatment options exist for autism including behavioural options. Behavioural 
interventions which include applied behavior analysis are used to address behavioural problems 
in autistic youths. An initial behavioural assessment, called a functional analysis, is conducted 
prior to behavioural intervention. Functional analyses are controlled observational sessions that 
are performed to objectively figure out the main motivating factor for a child’s behavior which 
may include seeking attention, accessing a favoured item, avoiding doing something or other 
rewarding characteristics of the behavior. Although behavioural interventions have been 
successful in decreasing maladaptive behavior in autistic children, timely access to trained 
personnel and therapists in this intervention is often restricted (Posey et al., 2008). 
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 When behavioural interventions are not fully effective, medication-based treatments are 
often taken into consideration. A survey of psychotropic drug use in children with pervasive 
developmental disorders (PDD) found that about half of the subjects are presently being 
prescribed a psychotropic drug and that 16.5% are taking an antipsychotic drug. Antipsychotics 
are most frequently used to alleviate mood and behavioural disturbances including irritability, 
aggression and agitation. Studies have suggested that about 30% of children and adolescents with 
PDD experience moderate to severe irritability, often accompanied by aggression directed 
towards others or themselves. Recently, risperidone was approved by the Food and Drug 
Administration (FDA) for the treatment of irritability in autistic children and adolescents. This is 
very noteworthy because Risperidone is the first drug to be approved in the treatment of autism 
and the first atypical antipsychotic to be approved for use in children and adolescents. 
Risperidone and other atypical antipsychotics, however, had become common in the treatment of 
autism well before its FDA approval and several published reports had suggested its clinical 
effectiveness (Posey et al., 2008). 
 Antiepileptic drugs (AEDs) are also widely administered to autistic individuals. There are 
several reasons why AEDs are used in ASD, including the high rate of co-occurring epilepsy in 
these individuals, the anecdotal reports that suggest improved communication and behavior in 
subjects with autism and epileptic discharges and the knowledge that some disruptive behaviours 
may be symptomatic of an associated affective disorder. Although the role of AEDs is not 
currently established, there is evidence that autism, epilepsy and affective disorders are 
commonly comorbid and that they may share a common neurochemical substrate. This substrate 
is the common target of the psychotropic mechanism of action of different AEDs (Di Martino 
and Tuchman, 2001). A survey study of individuals with ASD, conducted in the early 1990s, 
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found that 15.2% of individuals were medicated with AEDs with the most common for the 
treatment of epilepsy being carbamazapine, valproic acid and phenytoin. Studies that have 
examined the behavioural and cognitive effects of AEDs in ASD have found that valproate 
monotherapy reduced repetitive behaviours and irritability in autistic individuals. Valproate has 
also been reported to improve core behavioural symptoms in autistic children with and without 
epilepsy and to significantly improve autistic symptoms in children with subclinical epileptic-
like discharges on EEG. Other AEDs that have been reported to improve cognitive effects in 
autistic children include lamotrigine, levetiracetam, topiramate and carbamazepine (Frye et al., 
2013). 
The Ketogenic Diet 
Background 
 
 The Ketogenic Diet (KD) has been successfully used to treat intractable epilepsy since 
the early 1920s. It is high in fat, low in carbohydrates and provides sufficient proteins for growth 
(Hartman et al., 2007). Fasting has been known to be an effective antiepileptic treatment for a 
long time and works for a wide range of seizure disorders. However, because it is an 
unsustainable method of treatment, KDs were developed to mimic the physiological effects on 
the body of fasting (Mantis et al., 2004). The KD has been so called because maintenance of the 
diet results in a sustained state of ketosis in the body (Hallböök et al., 2012). Because the diet 
provides insufficient carbohydrate to fuel the body’s energy needs, energy is largely gained from 
fatty acid oxidation in the mitochondria. Large amounts of acetyl-CoA are generated during high 
rates of fatty acid oxidation resulting in the synthesis of the three ketone bodies beta-
hydroxybutyrate, acetoacetate and acetone mainly in the liver. The metabolic efficiency of the 
Krebs cycle is increased and excess acetyl-CoA is diverted into the production of ketone bodies. 
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Ketone bodies then end up in circulation, raising serum levels substantially, and are utilized by 
extrahepatic tissues, including the brain, as an energy source. Usually glucose is utilized as fuel 
for the human brain – fatty acids cannot be used as they do not cross the blood-brain barrier. 
Ketone bodies enter the brain in direct proportion to ketosis. Normally, ketone utilization by the 
brain is minimal but while on the KD ketone bodies partly replace glucose as fuel for the brain 
(Hartman et al., 2007).  
 The KD has been used to effectively treat various forms of drug-resistant epilepsy 
(Hallböök et al., 2012). Currently, several types of KD exist for epilepsy treatment with the most 
common being the traditional KD. It is based on long-chain saturated fats with a low percentage 
of carbohydrates and proteins in a ratio of 4:1 with there being four times the amount of fats to 
protein and carbohydrate combined (Hartman et al., 2007). In the clinical setting, patients are 
usually given 1g of protein per 1kg of body weight, 5-10g of carbohydrates and the remainder of 
daily calories in fats. The KD minimizes body glucose levels – 55-75mg/dl serum glucose 
without causing caloric restriction or malnutrition (Hallböök et al. 2012). A typical day on the 
KD for a three year old child is shown below in a table by Zupec-Kania & Spellman (2008).  
Breakfast 40g 36% Heavy cream 
32g Sausage links 
24g Avocado- Haas 
5g Canola oil 
Lunch 
 
40g 36% Heavy cream 
18g Sliced turkey breast 
22g Raw cucumber slices & celery sticks 
22g Mayonnaise 
Dinner 40g 36% Heavy cream 
20g Baked cod 
43g Roasted cauliflower 
23g Butter 
Snack 10g Sliced strawberries 
28g 36% Whipped heavy cream 
Table 1: A typical day on the 
KD for a 3 year old child. The 
majority of fats are from heavy 
cream, vegetable oils, and 
butter, which represent medium 
and long chain triglycerides. 
Adapted from Zupec-Kania & 
Spellman, 2008. 
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The Ketogenic Diet and Autism 
 
 The KD has been proposed as a treatment to improve the symptoms of ASD. Many 
autistic children are medicated with anti-epileptic drugs (AEDs) for the treatment of epilepsy as 
well as behavioural disturbances. A meta-analysis of children with ASD on AEDs found that 
85% of the literature reviewed reported that children on an active AED (valproic acid, 
carbamazepine and lamotrigine) showed improvement in their behavioural disturbances 
(irritability and aggressiveness) as well as in their core ASD symptoms of sociability and 
communication regardless of whether their seizures improved. This suggests shared underlying 
biology between epilepsy and ASD which means that the KD, an effective anti-epileptic, can 
potentially be therapeutic against ASD (Di Martino & Tuchman, 2001). 
 A study was conducted on the island of Crete where 30 epileptic children were treated 
with KD. The children were between 4 and 10 years of age and displayed autistic behaviour. The 
KD was administered for six months that included four weeks of continuous administrations 
followed by a two week diet-free break. Improvement was reported by 18 of the 30 children, 
who adhered to the diet for a year, in their Childhood Autism Rating Scale scores. Significant 
improvement (>12 units) was reported by 2 patients, average improvement (>8-12 units) in eight 
patients and minor improvement (2-8 units) in eight patients (Evangeliou et al., 2002). These 
results provide further support for the hypothesis that the KD could improve behavioural 
symptoms and serve as a treatment option for ASD. 
 Our lab conducts research with an autistic model of mice and the KD that gives further 
credence to this hypothesis. The BTBR mouse models the three core behavioural deficits of ASD 
– sociability, communication and repetitive behaviours. Our lab showed, in a recently published 
study, that juvenile BTBR mice fed a diet constituting a 6.6:1 ketogenic ratio for three weeks 
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showed improved behavioural symptoms when behavioural tests were carried out at eight weeks 
of age. Specifically, the BTBR displayed improved sociability in the three-chamber test, reduced 
self-directed repetitive behaviour in the three-chamber and single-chamber test and improved 
social communication of food preference (Ruskin et al., 2013). These results are illustrated in 
Figure 2 below. Based on these promising results, our lab has been motivated to explore the 
effects of the KD in other rodent models of ASD.  
 
 
 
 
. 
 
 
 
Figure 1: Previous work conducted in our lab on the effect of the KD on behavioral symptoms 
in the BTBR mouse model of ASD. The KD significantly increased sociability and 
communication and reduced repetitive behaviors. 
 
The EL Mouse Model 
 
 In this project, the EL mouse model of ASD and epilepsy was used. The model was 
discovered in 1954 to be a mutation from the outbred non-epileptic DDY strain and were 
validated as a model of epilepsy in 1976. The EL mouse has since been used as a model of 
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multifactorial idiopathic generalized epilepsy (Meidenbauer et al., 2011). Along with their 
seizures, EL mice experience incontinence, vocalisations, loss of postural equilibrium among 
other symptoms (Meidenbauer et al., 2011; Suzuki 1976). EL mice experience handling-induced 
seizures by post-natal day 50-70. Male EL mice are more susceptible to seizures than females at 
60-90 days of age but this disparity disappears by 120 days of age (Meidenbaur et al., 2011).  It 
was also found that EL mice display paroxysmal discharges and abnormal brain plasticity, 
further strengthening their epileptic phenotype (Suzuki, 2013).  
 Previous studies have also found abnormal social behaviours in EL mice. One study 
found that an EL mouse placed in a novel cage with an unfamiliar mouse was less inclined to 
interact with and explore the unfamiliar mouse (Turner et al., 2007). We have also noticed in our 
lab that female EL mice exhibit abnormal maternal urges, often consuming her newborn pups. 
EL mice have also exhibited developmental delays that include abnormal habituation to a new 
environment and hyperactivity in some tests (McFadyen-Leussis and Heinrichs, 2005). 
 Another recent study reinforced the fact that the EL mice display an autistic phenotype as 
well (Table 2). The EL mice were compared to the non-epileptic original DDY strain which 
served as controls and were subjected to behavioural tests such as the light-dark compartment, 
social transmission of food preference, open field, myoclonic jumping tests as well as validation 
of their epileptic phenotype. In all tests, the EL mice were found to exhibit a robust autistic 
phenotype compared to DDY controls. The EL mouse model is the first model of both epilepsy 
and autism that consistently demonstrates both phenotypes clearly. Thus, the EL mouse model 
was determined to be a reliable model for autism and epilepsy for this project.  
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Table 2: A summary of the fidelity of the EL mouse as a model of autism. From Meidenbauer et 
al., 2011.  
 
  
We have previously investigated the behavioural effects of our strict KD (6:1 ketogenic ratio) on 
both male and female EL mice. However, beneficial effects were seen in the females only. 
Although, our strict KD has been shown to be effective in reversing symptoms in the BTBR and 
improving those in EL females, its severity limits its clinical applicability. In this study, we 
compared the behavioural effects of our moderate KD, our strict KD and a control diet on EL 
females only since no diet effects were seen in the males on the strict diet. 
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Thesis Overview and Hypothesis 
 
 The current study compared the effects of our strict KD (6.6:1 ketogenic ratio), our 
moderate KD (3:1 ketogenic ratio) and a control diet on female EL mice. Specifically, the diets’ 
effects on autistic behavioural symptoms, weight and blood levels of glucose and beta-
hydroxybutyrate of the mice were examined. Based on previous research on the KD in the BTBR 
mouse model of autism, we predicted that the two KDs would improve autistic behaviors, 
increasing sociability and communication and reducing repetitive behaviours, as well as increase 
blood beta-hydroxybutyrate and decrease blood glucose and weight. We wanted to find out 
specifically how effective our moderate KD was when compared to our strict KD and a control 
diet.  
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METHODS 
Animals 
 
Female EL mice were weaned at three weeks of age and housed in groups of two to six 
animals per cage. They were fed standard rodent pellet chow and water ad libitum for two weeks 
and then at five weeks of age, they either remained on the standard rodent chow (n = 18) which 
became a control diet (CD), or were switched to either the restrictive ketogenic diet (strict KD - 
6.6:1 fats to carbohydrates and proteins, BioServ) (n = 18) or to the milder ketogenic diet 
(moderate KD – 3.2:1 fats to carbohydrates and proteins, BioServ) (n = 18). The mice were fed 
their respective diets ad libitum for another three weeks, after which behavioural testing was 
performed. Behavioural testing involved the three chamber test which included the three 
chamber sociability test, social approach test and test for self-directed repetitive behaviours. 
Blood testing, where blood ketone and glucose levels were measured, was also carried out after 
behavioural testing, as well as weight measurements. The three chamber tests were video 
recorded to allow for scoring by two independent viewers in order to validate the data. 
 
 
 
 
 
 
Figure 2: Study timeline and testing protocol 
 
 
EL mice born 
and nursed 
for 3 weeks 
Weaned and 
fed standard 
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to strict KD or 
to moderate KD 
At 8 weeks of 
age, 
behavioural 
and blood 
testing was 
done as well as 
weight 
measurements 
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Blood Testing 
 
Blood ketone (β-hydroxybutyrate) and glucose levels were measured at eight weeks of 
age after all behavioural testing but STFP ended. The mice were first generally anesthetised by 
carefully placing them in a plastic container that held a small quantity of isofluorane. Tail blood 
was then taken, after which they were returned to their home cage to recover. The blood was 
analysed using a Precision Xtra meter and glucose and ketone strips. 
Behavioural Testing 
Three-Chamber Test 
 
The three-chamber test tests for sociability and self-repetitive behaviours in autistic 
models of mice (Moy et al., 2004). The apparatus was made of Plexiglas and consisted of three 
equally-sized chambers (42.5 cm x 19.1 cm x 22.2 cm) separated by removable doors. These 
doors separate the center chamber from the two side chambers. A wire cage (inverted pencil cup) 
was set against the back wall of each of the two side chambers with cement blocks placed on top. 
These were present for the entirety of testing. 
Before the start of a testing session, the cage of test mice were placed in the testing room, 
with the cage filter lid removed, to habituate for 30 minutes. Concurrently, the stranger mice 
(adult, female, albino CD1) were gently placed under the two wire cups in the apparatus and left 
to habituate for 30 minutes as well (Figure 2A). Afterwards, the stranger mice were returned to 
their cage and the apparatus was washed with warm water and soap.  
Then, in another habituation phase, the subject mouse was placed in the center chamber 
with the doors down and the lid off for 10 minutes. Following this period, a video-recording 
camera was set up to record the activity of the test mouse in the three 10 minute phases of the 
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three chamber test. In the first recorded phase, the doors of the side chambers were removed and 
the lid placed on top of the apparatus. The mouse was allowed to freely wander into the side 
chambers (Figure 2B) and this phase tested for side bias. At the end of the first phase and before 
the start of the second, the test mouse was gently guided back into the center chamber and the 
doors replaced. A stranger mouse was then placed under one of the wire cages in a side chamber, 
after which the doors were once again removed to allow the test mouse full access to the side 
chambers (Figure 2C). This phase tested for social preference. For the third and final phase, the 
test mouse was again guided into the center chamber and the doors replaced. A second, novel 
stranger mouse was then put under the remaining wire cup in the other side chamber. The doors 
were then removed as before (Figure 2D) and this phase tested for preference for social novelty. 
At the end of the testing session, all mice were returned to their home cage and the entire three 
chamber apparatus, including the removable doors, wire cages and cement blocks, was washed 
and dried.  
Sociability 
 
Two independent scorers used the recorded video and manual timers to measure how 
much time the test mouse spent in each chamber, defined as over half of the mouse’s body being 
in a chamber. The measurements were used to compare how much time the test mouse spent in 
the side chamber containing the stranger mouse (target chamber), in phase two, with the amount 
of time she spent in the empty chamber. In phase three, the time the test mouse spent with the 
first stranger mouse was compared to the time she spent in the chamber with the novel stranger 
mouse (target chamber).  
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Social Contact 
 
The three chamber test can also be used to test for social contact (Defensor et al., 2011). 
Social contact is a measure of the test mouse’s sociability and how much contact there is 
between her and the stranger mice. The total amount of social contact was measured in the 
second and third phases only and was defined as any contact by the front half of the test mouse 
and the stranger mouse/cage. The behaviour was typified by the test mouse having her paws or 
face against the stranger mouse’s wire cage, climbing the cage, having direct physical contact 
with the stranger mouse through sniffing with whiskers and/or face and other body parts 
touching. Social contact was measured because during the three chamber test, the mouse could 
have been in the target chamber but was not socializing with the stranger mouse. Two 
independent scorers measured social contact times in all female EL mice undergoing the three 
dietary treatments. 
 
 
 
 
 
 
 
 
 
  
          Figure 3: Outline of the Three Chamber Test. (Svedova, 2011) 
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Self-Directed Repetitive Behaviour (A) 
 
The three chamber test was also used as a test for self-directed repetitive behaviour or 
grooming. In this case, the amount of time spent grooming by the test mouse in the first two 
phases was measured in all chambers. Grooming was defined as licking, biting and scratching, 
including cleaning the face with the paws, biting the hind quarters, licking the tail to name a few. 
Two independent scorers manually measured grooming time.  
Single Chamber Test 
 
Self-Directed Repetitive Behaviour (B) 
 
 Before testing began, the home cage of test mice would be placed in the testing room 
with the filter top off to habituate for 30 minutes. One test mouse was then placed in a clean, 
empty, transparent enclosure (7.5”x11.5”x5”) covered by a lid to habituate for 10 minutes. 
Afterwards, a video-recording camera was set up to record the test mouse’s activity for the next 
10 minutes. The time the mouse spent grooming (see Three Chamber: Self-Directed Repetitive 
Behaviour) was scored by two raters and the scores were averaged. The single chamber test took 
place on a different day than the three-chamber test. 
Social Transmission of Food Preference (STFP)  
 
 The STFP measures attention/social awareness of an observer mouse. Twenty-four hours 
before testing, all chow was removed from the cage and the mice were habituated to eating 
unflavoured powdered food from a jar. The jars (2” diameter, 1.5” height) were made of glass 
and had rounded bottoms. After habituation, one mouse was chosen randomly from the cage and 
designated the demonstrator mouse. The demonstrator mouse was placed in a separate cage, 
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similar in size and with similar enrichments. She and the observer mice who were left behind in 
the home cage were deprived of food and fasted for 18 hours.  
 After the fast, one jar that was filled with bedding and topped by a flavoured food 
(trained flavour) was placed into the demonstrator mouse’s cage for two hours. The flavor used 
was either cocoa or cinnamon (2% cocoa and 1% cinnamon) and was alternated among test 
groups. If the test mouse had eaten at least 0.5 grams of food, she was returned to her home cage. 
If not, she remained in isolation for hour long intervals until she had done so and was then 
returned to her home cage. The demonstrator mouse interacted with the observer mice for 30 
minutes, during which time it is thought that she passively communicated olfactory cues to the 
observer mice to identify the trained flavour (Wrenn et al., 2003).  
 Afterwards, the observer mice were placed in separate cages and given a choice between 
two flavoured foods: the trained flavour and an untrained or novel flavour. Cinnamon and cocoa 
were alternated as either the trained or untrained flavour depending on which the demonstrator 
mouse was fed. The observer mice were allowed to feed for two hours and the jars were weighed 
before and after to determine how much food the mice had eaten. Healthy mice engage in STFP 
during the 30 minute interaction with demonstrator mice and prefer the trained flavour because 
they have deemed it safe after recognising it from the still alive demonstrator mice.  
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Figure 4: Social transmission of food preference test. The demonstrator mouse is presented with 
a trained flavour (either cocoa or cinnamon) then interacts with observer mice who are then 
presented with a choice between the trained and an untrained flavour (from poster by Masino et 
al.). 
 
Statistical Analysis 
 
Data from the three chamber and single chamber tests was scored by two independent 
raters and at least one scorer was blind to dietary treatment. All data was entered into Excel 
spreadsheets then analysed using the SigmaPlot software program. Data from all tests - the single 
chamber and three-chamber tests and blood and weight - were statistically analysed using One 
Way ANOVA followed by a post-hoc (Student Neuman-Keuls). Data outliers were determined 
and eliminated using the Grubbs test. 
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RESULTS 
 
Weight and Blood 
 
Weight 
 
 Mice on the moderate KD weighed significantly more than mice on the CD and mice on 
the strict KD (Figure 5). In the past, we have seen that male BTBR and female EL mice on the 
strict KD lost weight compared to animals on the CD. Here, however, we see that female EL 
mice on the strict KD only trend towards losing 
weight compared to mice on the control diet 
(p=0.059). 
   
 
Figure 5: Weight data for female EL mice on CD 
(n=15), strict KD (n=18) and moderate KD (n=18). 
Mice on the moderate KD weighed significantly more 
than mice on the CD and mice on the strict KD. 
***=p<0.001 
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Blood Glucose Levels 
 
Mice on the strict KD had significantly lowered blood glucose levels compared to mice 
on the CD while no difference was seen in blood glucose levels in animals on the CD and those 
on the moderate diet (Figure 6). The strict 
KD, therefore, reduced blood glucose 
levels more effectively than the moderate 
KD. 
 
 
Figure 6: Blood glucose data for female 
EL mice on CD (n=15), strict KD (n=18) 
and moderate KD (n=18). Mice on the 
strict KD had significantly lower blood 
glucose compared to animals on the CD. 
*=p<0.05 
 
 
 
 
 
 
Blood Ketone (Beta-hydroxybutyrate) Levels 
 
 Mice on both KD groups had significantly increased ketone levels compared to mice on 
the CD (Figure 7). Mice on the strict KD also had significantly increased ketone levels 
compared to mice on the moderate KD. Therefore, the strict KD was more effective at increasing 
blood ketone levels than the moderate KD.  
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Figure 7: Blood ketone data for female 
EL mice on CD (n=15), strict KD 
(n=18) and moderate KD (n=18). Mice 
on the KDs had significantly elevated 
blood ketone levels compared to mice 
on the CD. Mice on the strict KD also 
had significantly increased ketone 
levels compared to mice on the 
moderate KD. ***=p<0.001 
 
 
 
 
 
 
Behavioural Testing 
 
Three-Chamber Test 
 
The three-chamber test was used to determine sociability by measuring chamber time and 
social contact. The three-chamber test was also used to quantify repetitive behavior (grooming).  
Chamber Time 
 In chamber time, mice on both the strict and moderate KDs showed increased sociability 
in phase 2, the preference for sociability phase, compared to phase 1, the non-social phase 
(Figure 8). Mice on the control diet, however, showed no significant differences between phases 
which indicates a diet effect. Therefore, both KDs increased sociability in the preference for 
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sociability phase.  There were no significant differences between phases from phase 1 to 3 or 
from 2 to 3 in any of the diets or between diets in phase 3. 
 
Figure 8: Sociability data from chamber time of the three-chamber test. Female EL mice on the 
CD (n=18), moderate KD (n=18) and strict KD (n=17) were tested. Mice on the moderate and 
strict KDs showed increased sociability within phases from phase 1, the non-social phase, to 
phase 2, the preference for sociability phase. #=p<0.05 
 
Social Approach 
 
 The second and third phases of the three-chamber test were also used as a measure of 
social contact. The total time that female EL mice (n = 18) on CD, moderate KD and strict KD 
spent in contact with stranger mice was recorded (Figure 9). In phase 2, where one stranger 
mouse was present, mice on both KDs showed significantly increased social contact compared to 
mice on the CD. In phase 3, the preference for social novelty phase, however, only mice on the 
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strict KD showed significantly increased social contact compared to mice on the CD. 
    
Figure 9: Sociability data from social approach in the three-chamber test. Data was obtained 
from female EL mice (n=18) on the CD, strict KD and moderate KD during the A) second and 
B) third phases of the test. In the second phase, mice on both the moderate and strict KDs 
showed increased social contact compared to mice on the CD. In the third phase, however, only 
mice on the strict KD showed significantly increased social contact compared to mice on the CD. 
*=P<0.05 
 
Self-Repetitive Behaviour 
 
 The first two phases of the three-chamber test were used to determine the amount of time 
spent grooming in a social versus a non-social setting. Time spent grooming by female EL mice 
on the CD, strict and moderate KDs was recorded (Figure 10). In phase 1, the non-social phase, 
mice on both the strict and moderate KDs showed decreased grooming compared to mice on the 
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CD. However, in phase 2, the social phase, mice on the moderate KD increased their grooming 
compared to phase 1.  
 
Figure 10: Results from the three-chamber test of self-repetitive behavior (grooming). Female 
EL mice on the CD (n=18), moderate KD (n=17) and strict KD (n=17) were tested. Mice on the 
KDs groomed significantly less in phase 1 than mice on the CD. However, mice on the moderate 
KD groomed significantly more in phase 2 than in phase 1.  
 
Single Chamber Test 
 
 The amount of time spent grooming in the single chamber test was also used as an 
indicator of self-directed repetitive behavior. Grooming time was measured from female EL 
mice on the CD, moderate and strict KDs (Figure 11). No significant diet effects were seen in 
animals on any diet.  
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Figure 11: Results from the single chamber test of self-repetitive behavior (grooming). Female 
EL mice on the CD (n=18), moderate KD (n=13) and strict KD (n=18) were tested. No diet 
differences were observed. 
 
Social Transmission of Food Preference 
 
 The STFP experiment was used to test communication in female EL mice on the CD, 
strict and moderate KDs. There was no dietary effect on the amount of trained food consumed by 
mice on the KDs compared to mice on the CD.  
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Figure 12: Data from the STFP test in female EL mice on the CD (n=14), strict (n=13) and 
moderate (n=14) KDs. No dietary effect was observed on the amount of trained food consumed 
by the mice. 
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DISCUSSION 
 
According to the data collected, this study found that the moderate or clinical strength 
KD had very similar behavioural effects in the female EL mice compared to the strict KD. These 
results represent the first time that the efficacy of the moderate KD has been compared with that 
of the strict KD in an autistic mouse model with favourable results in terms of behavioural 
benefits. We had hypothesized that both diets would improve autistic behaviors, increasing 
sociability and communication and reducing repetitive behaviours, as well as increase blood 
beta-hydroxybutyrate and decrease blood glucose and weight. Our hypothesis was largely 
supported with the key exception being that blood glucose was not reduced as an effect of either 
of the KDs. 
Previous Studies and Inconsistencies 
 
 A previous study was conducted in this lab by Ruskin et al., 2013 on another autistic 
mouse model, the BTBR. In this study, the effects of the strict KD on blood chemistry and 
autistic behaviours were also investigated. Based on the blood chemistry effects of this study 
where blood ketones were significantly increased, inducing ketonemia, it was expected in the 
current study that such a significant increase would also occur with both the strict and moderate 
diets which indeed took place. It was also predicted, based on the results of this study that the 
strict diet significantly lowered blood glucose, that both the strict and moderate diets would have 
similar effects in the EL mice in the current study. However, only the strict diet significantly 
reduced blood glucose in the EL mice while the moderate diet had no effect. This is of particular 
interest because reduced blood glucose is supposed to be one of the hallmark effects of the KD 
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and this has been hypothesized to play a role in the anti-seizure mechanism of the diet and 
potentially in the mechanism for alleviating autistic behaviours (Ruskin et al., 2013).  
 In the BTBR study by Ruskin and colleagues, it was found that the strict diet reduced 
autistic behavioural symptoms. In this study, BTBR mice on the strict KD spent significantly 
more time in the chamber with a stranger mouse in the second phase of the three chamber test 
compared to mice on the control diet in the same phase. There was also increased sociability 
within phases from phase 1 to phase 2. In the current study, both diets increased sociability in 
phase 2, the preference for sociability phase, from phase 1 but did not differ significantly from 
mice on the CD in phase 2. Also, in the BTBR study, the mice on the strict KD showed a very 
significant increase in social contact in phase 3. In the current study, both diets showed a 
significant increase in social contact in phase 2 but only the strict diet showed a significant 
increase in phase 3.  Furthermore, the strict KD very significantly reduced self-repetitive 
behaviour in phases 2 and 3 of the three chamber test in BTBR mice while in the EL mice, 
significant grooming time reductions were only seen in phase 1 for mice on both diets. Finally, 
KD feeding in BTBR mice improved social communication in the social transmission of food 
preference test as mice ate significantly more of the trained flavor than the untrained flavor while 
no diet effects were observed in the EL mice. Thus, there are similarities between the strains for 
certain autistic traits but differences for other traits. These differences reflect the great variation 
of symptoms present in ASD which fall on a spectrum. 
 In this lab, we have previously found that the EL mice exhibited autistic behaviors in 
some tests but not others. Specifically, we have seen sex differences in autistic symptoms. 
Unexpected results include that EL male and female mice were able to perform social 
transmission of food preference, considering a previous study found that EL mice showed 
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significantly less preference for the trained flavor (Meidenbauer et al., 2011). The animals in the 
previous study were fed the strict KD. When the males in that study were compared with the 
females in the current study on the strict diet, we saw that males on the diet showed no 
significant weight changes or differences in blood glucose levels, sociability or self-repetitive 
behaviours compared to mice on the CD. They did, however, show increased ketone levels as 
expected. Sex differences have also been seen in BTBR mice (Defensor et al., 2011) where 
females were seen to have higher levels of sociability in social proximity tests than males. The 
males, however, consistently displayed autistic behaviours including avoidance of contact, 
increased self-grooming and less time spent engaged in social interactions to name a few. Autism 
is a heterogeneous condition (Lord et al., 2000) where no two individuals present with the same 
symptoms and symptoms are varied and fall on a spectrum. The autistic symptoms of the EL and 
BTBR models could therefore fall on such a spectrum which may explain the differences seen in 
the effects of the strict KD on autistic symptoms in the two models.  
Very interesting also is the fact that contrary to our hypothesis, the moderate diet did not 
reduce blood glucose but animals on this diet still showed improved sociability in the preference 
for sociability phase in the three chamber test as well as improved social contact in the same 
phase. Grooming time was also reduced in phase 1 of this test. These results indicate that a more 
moderate ketogenic ratio may not result in lowered blood glucose as has previously been seen in 
a more strict version of the diet (Ruskin et al., 2013) and more importantly, that lowered blood 
glucose may not be necessary for improvement in autistic behaviours to occur as had been 
previously hypothesized. Furthermore, the moderate diet caused a very significant increase in 
weight in animals, indicating an absence of caloric restriction.  Studies have shown that the KD 
manages epilepsy best when administered in restricted amounts and since fasting lowers blood 
42 
 
glucose levels, Seyfried and colleagues suggested that caloric restriction might contribute to the 
antiepileptic and anticonvulsant effects of the KD (Greene et al., 2001; Seyfried et al., 2004; 
Mantis et al., 2004; Eagles et al., 1999). However, in the current study beneficial behavioural 
effects were seen in the absence of caloric restriction where a very significant weight increase 
was seen in the 3:1 moderate KD, suggesting that caloric restriction is not necessary for the 
beneficial effects of the KD. The study by Seyfried et al. tested a 3.4:1 KD in female EL mice as 
well while the study by Eagles et al. tested a 7.7:1 KD in male Sprague-Dawley rats. The 
differences in sex, animal species and ketogenic ratio in these studies versus the current study 
may or may not have influenced the difference in results regarding the necessity for caloric 
restriction in the efficacy of the KD, and more studies are needed to determine if a relationship 
exists between these variables. It is also possible that ASD and epilepsy may have different 
neurobiological mechanisms so that caloric restriction may be highly beneficial for the KD’s 
antiepileptic effects but unnecessary for its autistic behavioural effects. 
Proposed Mechanisms of the Ketogenic Diet 
 
 Autistic spectrum disorders and epilepsies are heterogeneous disorders that have diverse 
etiologies and pathophysiologies. The high rate of co-occurrence of these disorders suggest 
potentially shared underlying mechanisms (Di Martino and Tuchman, 2001). Although the 
efficacy of the KD against epilepsy has been acknowledged, its antiepileptic mechanism is still 
unknown. It is proposed that the behavioural effects of the KD are due to the very high levels of 
blood ketones which are thought to have neuroprotective effects. One theory proposes that beta-
hydroxybutyrate may provide a more efficient energy source unit oxygen than glucose (Veech et 
al., 2001). The diet also appears to induce mitochondrial biogenesis as electron micrographs of 
the dentate/hilar area of the hippocampus exhibited a 46% increase in mitochondrial profiles in 
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rats fed the KD (Bough et al., 2006). The combination of these factors may account for neurons’ 
increased ability to withstand metabolic challenges that would normally deplete the resilience of 
neurons resulting in their demise (Gasior et al., 2006). Acetoacetate has also been shown to be 
neuroprotective against glutamate-mediated apoptosis, a major mechanism that occurs upon cell 
injury (Gasior et al., 2006). Additionally, the KD may be neuroprotective by increasing GABA 
levels which consequently increases GABA-mediated inhibition (Yudkoff et al., 2001). The diet 
may also confer neuroprotection by enhancing antioxidant mechanisms by reducing free radical 
production (Veech, 2004) and by controlling Reactive Oxygen Species (ROS) formation (Ziegler 
et al., 2003; Freeman et al., 2006). The diet may also protect against different forms of cell 
death. For example, the diet protected against apoptosis in mice induced by the glutamate 
receptor agonist and excitotoxin kainate, shown by reductions in apoptosis markers (Noh et al., 
2003). Inflammation has also been hypothesized to contribute to the development of chronic 
epilepsy and fasted rats have shown increased expression of the cytokine interferon-γ in the 
hippocampus which has been shown to protect against excitotoxic cell death (Lee et al., 2006). 
The role of decreased carbohydrates as a neuroprotective mechanism has also been studied and 
was found to be protective against hippocampal damage and functional neurological deficits 
caused by the seizure-inducing excitotoxin kainite as well as against glutamate- and oxidative 
stress-induced neuronal death in culture (Lee et al., 1999). It has also been found that the KD can 
reduce seizures in mice by increasing activation of adenosine A1 receptors (Masino et al., 2011). 
Figure 13 summarises these proposed mechanisms.  
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Figure 13: Schematic showing proposed anti-convulsant mechanisms of the Ketogenic Diet.  
 Looking at proposed mechanisms of autism, evidence of parallels with epilepsy were 
found. Several lines of evidence suggest that an impairment of GABAergic transmission 
contributes to the development of ASD. In particular, it has been hypothesized that at least some 
forms of autism result from an imbalance between excitation and inhibition in circuits involved 
in sensory, mnemonic, social and emotional processes. Changes in GABAA and GABAB 
receptors have been found in brain samples from ASD patients. The resulting hyperexcitability, 
due to impaired GABAergic transmission, could thus disrupt the normal formation of cortical 
maps leading to a relatively unstable state. This altered GABAergic function may also reduce the 
threshold for developing seizures (Pizzarelli and Cherubini, 2011). Such excitatory-inhibitory 
defects have also been found in mouse models of autism (Gogolla et al., 2009). Urakubo and 
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colleagues also found that maternal exposure to high-dose lipopolysaccharide, a well-
characterized model of infection in rodents, in pregnant rats decreases TNF-α in the fetal brain. 
Given the mounting evidence that cytokines play important roles in the development of neurons 
and glial cells, changes in levels of these pro-inflammatory cytokines in the fetal environment 
may contribute to abnormal brain development associated with prenatal exposure to infection 
(Urakubo et al., 2001). Mitochondrial dysfunction has also been theorized to play a part in the 
mechanism of autism. One study conducted with autistic children found a high prevalence of 
mitochondrial dysfunction in children presenting with full syndrome autism. Mitochondrial 
dysfunction could greatly amplify and propagate brain dysfunction, such as that found in autism, 
given that the highest levels of mtDNA abnormalities are observed in post-mitotic tissues with 
high energy demands (e.g., brain) (Giulivi et al., 2010). Given these hypothesized mechanisms 
of autism, the proposed therapeutic mechanisms of the KD that may cause improved autistic 
behavioural effects are summarized in Figure 14 below. 
 
Potential for Use as Diet Therapy 
The strict KD has been shown exhaustively to be neuroprotective in many ways but 
particularly in epilepsy and more recently autism. Autism is often co-morbid with epilepsy 
suggesting a shared underlying mechanism which prompted investigations into the KD’s efficacy 
against autism. Our lab has now shown that our strict KD is efficacious in two mice models of 
autism, one also being a model for epilepsy. However, the severity of our strict KD makes it 
clinically inapplicable which further prompted the development and use of our moderate KD. We 
have now also shown that the moderate KD has very similar efficacy as the strict KD in 
alleviating autistic behavioural symptoms in an animal model. This moderate KD, being 
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clinically relevant, can be potentially beneficial in children with ASD in improving core 
behavioural symptoms. To date, no drug has been shown to have significant impacts on the core 
symptoms which has been problematic, for without improved social relatedness and 
communication and reduced repetitive behaviours, children with autism would not be able to 
benefit from social services, educational programs and behavioral interventions, according to 
experts (Anthes, 2014). Risperidone and apiprazole are the only drugs currently approved by the 
FDA to treat irritability associated with ASD and not any of the core symptoms (Anthes, 2014; 
McDougle et al., 2005). As it stands, the ketogenic diet is an established, effective non-
pharmacologic treatment for intractable childhood epilepsy (Kossoff et al., 2008) with very 
manageable initial side effects. Due to the evidence that it may improve the core symptoms of 
Figure 14: Schematic showing proposed autistic-relieving mechanisms of the Ketogenic 
Diet. These overlap with its therapeutic anti-convulsant mechanisms and may provide 
evidence for shared mechanisms of the two disorders. 
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ASD, where other pharmacological and non-pharmacological treatments have failed, further 
studies are warranted into the efficacy of the moderate KD in children with ASD. 
 
SUMMARY AND CONCLUSIONS 
 
 In summary, we found that the moderate KD was similarly efficacious to the strict diet in 
improving behavioural symptoms in the EL mouse model of autism. This is particularly 
important because it suggests that the clinical strength KD, the moderate KD, can be potentially 
beneficial for children afflicted with ASD. The KD has shown efficacy in treating the core 
behavioural symptoms of ASD and is an established treatment option for intractable childhood 
epilepsy. Therefore, future studies are warranted to determine its efficacy in treating core 
behavioural symptoms in children. In addition, we found that the moderate KD did not reduce 
blood glucose, one of the hallmark blood chemistry changes associated with the diet, but still 
caused improved behavioural symptoms. Because of this associated blood chemistry change, it 
was hypothesized that this change along with increased blood ketones is necessary for the 
improved behavioural effects of the diet. However, the findings of this study suggest that 
decreased blood glucose may not be needed but just increased levels of blood ketones. One way 
to further investigate whether increased ketones and not blood glucose is necessary for autistic 
behavioural effects would be to have patients elevate their ketone levels through consumption of 
ketone body esters such as 1,3-butanediol monoester of beta-hydroxybutyrate and glyceryl-tris-
3-hydroxybutyrate (Hashim and VanItallie, 2014). Ketone ester-induced hyperketonemia is 
robust, convenient, and safe, and the ester can be taken regularly as a food supplement without a 
need to change the habitual diet (Newport et al., 2015). Data collected also showed that the 
moderate KD resulted in weight gain which indicates an absence of caloric restriction. Previous 
48 
 
studies have showed that the KD best manages epilepsy, which is hypothesized to share a 
common underlying mechanism with autism, when administered in restricted quantities. 
However, the findings of the current study suggest that caloric restriction may not be necessary 
for its beneficial effects in autism without epilepsy. 
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